It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Timely reviews keep plans relevant. This intro covers triggers and a simple process to revisit and revise your budget plan.
20,890 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
BYDFi joined Peru Blockchain Conference 2026 in Lima, marking a clear LATAM push as the region readies for tighter ru...
Oracle shares slide as Larry Ellison funds a bid to steer a $110 billion media empire, triggering regulatory hurdles ...
Robinhood accelerates its blockchain push to compete with Coinbase, while Base narrows its focus to trading, payments...
A decade-long fundraising effort across 16 states and 35 coastal organizations has helped revive the American oysterc...
A newly unsealed set of court filings details a 'honey-trap' scheme targeting a tech-family circle, underscoring how ...
The SEC's updated listing standards could cut the time to a Cardano spot ETF dramatically, using CME Group's Cardano ...
Arizona Senate Finance Committee advances a bill that could place XRP and DigiByte in a state Digital Assets Strategi...
Warner Bros. Discovery’s latest quarterly results underscore a tougher operating environment even as deal drama swirl...
Rackspace Technology posts a tighter loss and higher 2026 profit outlook after a solid Q4, even as shares slip follow...
A circulating XRPL proposal aims to build a dedicated sidechain for exchange-grade options trading, linking it back t...
A growing cohort of retirees is turning to a 3.56% yield strategy as grocery bills rise. The Invesco DBA ETF provides...